Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-04-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
2019年度独立董事述职报告
Regulatory Filings
2020-04-15 Chinese
独立董事关于第二届董事会第九次会议相关事项的独立意见
Regulatory Filings
2020-04-15 Chinese
广发证券关于上海美迪西生物医药股份有限公司2019年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (广发证券股份有限公司) regarding the 2019 annual verification of the deposit and use of raised funds by Shanghai Medicilon Inc. It references regulatory approvals, specific dates in 2019, and detailed financial data about the amount raised, usage, balances, and compliance with relevant laws and regulations. The document includes audit opinions, tables of fund usage, and compliance statements. It is not a brief announcement or a certification letter but a substantive report on the use of raised capital for the fiscal year 2019. This matches the characteristics of an Audit Report / Information (AR) as it focuses on the audit and verification of the use of raised funds, not a full annual report or earnings release. Therefore, the correct classification is AR with high confidence. FY 2019
2020-04-15 Chinese
关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the revision of the company's Articles of Association (公司章程). It details specific amendments to the company's governance rules, board responsibilities, shareholder meeting procedures, and other corporate governance matters. The document is not a full annual report, audit report, or financial statement, nor is it a transcript or earnings release. It is a formal announcement about changes to the company's governance documents, which is typical of Governance Information filings. The document is lengthy (over 11,000 characters) and contains detailed governance content rather than just a brief notice or a report publication announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2020-04-15 Chinese
公司章程（2020年修订）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Shanghai Medicilon Inc. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. It is a comprehensive governance document that sets out the internal rules and regulations of the company. There is no indication that this is an annual report, financial report, or announcement. The content aligns with governance information about the company's internal rules and board structure. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, not just an announcement or summary.
2020-04-15 Chinese
关于使用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Medicilon Inc. regarding the use of idle funds for cash management. It details the amount, purpose, types of financial products, risk control measures, and the decision-making process including board and independent director approvals. The document is a formal public announcement about a financing-related activity (cash management of idle funds) rather than a full financial report or earnings release. It does not contain financial statements or detailed financial results, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to the company's management of capital resources and investment of idle funds.
2020-04-15 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.